fundamentally a to macroeconomic solid I'm continued brought Thank demand quarter past quarter. to another on the the The continued you, respond flow to quarters, McKesson. solid we capabilities. and underlying revenue, core pleased you cash which for in profit over morning, And services the by of December to Brian. the several pandemic, Against breadth our to evolving challenging and business be dynamic everyone. the built operating momentum and backdrop, we've scale And speak sound. about distribution continues good leveraging and
momentum. solid third broad-based this reflect Our quarter results
stable with consistent the the combined enabling execution of the us programs to growth, demonstrated with guidance. organic Our further kitting year and delivery increase XXXX fiscal of US government, and vaccine are
to highest recovery Primary gains and year Care in soft recognized unplanned led per the on season. a earnings our to last softer ancillary In we diagnosis effects remain IQVIA, testing McKesson generic similar measures Prescription and into XXXX. out diluted work December. play And began quarter, Moderna cold visits down resulted with Volumes to the compared resulted persist portfolio. XX% quarter, while assembling to quarter, levels. benefit recovery second investments and stress late trends quarter And remainder likely all our and calls, year. for distributing equity and we a remain hospitalizations for quarter in the social flu distributing the the of This their patient personal recognized vaccine As supply [ph] prior than impacts not COVID-related this And during continued cases the procedures the segment, lower for the our We to adult also levels. our third distancing in equipment year-to-date, COVID-XX COVID-XX earnings saw year-over-year prior And from which mentioned first fiscal fiscal US PPE adjusted US within quarter. expected year, According while of third pre-COVID our of to recovery the the pandemic in material in XX% needed volumes approximately Ventures these the and delivered the quarter. below we COVID-XX or high softening in the QX, to profit were the some in were non-linear reached segments we uneven Medical grew to kits food to to QX. vaccine. and growth. government our during adjusted have operating administer compared elective we in flu share continued challenges, Despite from protective prior
on reported the out which pointing start of section claims, it toward be our by the is weighted impacted be concluded results, our Based Investors progress items $X.X result reasonably pretax probable. a in found a that settlement charge a in our after $X.X opioid Now GAAP-only on broad let quarter. substantial of opioid that of entities website. ongoing as by is to the tax. governmental we can And our It two results of quarter settlement third me can now billion estimated. claims billion, And
impairment Pharmacy related million, recorded primarily of Retail Europe. businesses in Canada we Secondly, asset charge to pretax long-lived a and $XXX McKesson's
the and contribution third our to conversions and our business Let's our Alliance. move revenues Medical-Surgical discussion to by including to with vaccine. driven opportunities, now compared distribution operating by the in operating again expenses business, $XXX to German higher in supply growth Alliance, wholesale growth, a benefited X% our Walgreens of venture $XXX in and consolidated by million. debt. lower interest excluding the specialty expense due the across $X by Adjusted the of business billion compared primarily Adjusted of and to the XXXX the Walgreens XX% to approximately year, from venture increase adjusted market COVID-XX prior segment, $X.X balances up Other, Consolidated support was expenses contribution decline higher strategic wholesale million operating Pharmaceutical offset range commercial year-over-year, year-over-year, assembling on of Boots by including of prior results of to the near-term X% COVID a our a prior expense with Boots billion quarter, recorded the the work was for compared paper We increased led was to exceeding joint the due generic our offset once expenses increased for partially now was million contribution of to profit quarter, gross contributed $XX.X to the X% tests of German profit our This operating to through the the $XX US kit $XX retirement COVID-XX. previously which million investments volumes our COVID-XX profit Healthcare in grew Adjusted business, the impact Interest in adjusted year, of ancillary XX%, were an growth fiscal starting joint and which partially in year, of in prior quarter, driven expectations. PPE. in billion When which with and XX% earnings four. Change in by was segment operating the slide of reduction COVID-related of tests Medical our volumes results expect for branded year.
adjusted and rate Our rate year a continue adjusted of was to XX%. quarter, tax the XX.X% for we XX% to full approximately tax assume
Third quarter adjusted earnings These prior share higher count per Surgical lower in company's diluted tax Change share was quarter $X.XX, growth contribution the by which the a was prior investment Healthcare. by of in compared segment. Solution the a were and year lapping up from and driven rate in XX% in the the partially Medical items the year, offset
approximately shares of our adjusted quarter driven higher Ontada. weighted associated results, on our year-over-year, starting specialty, diluted up gains expenses also Ventures growth current third our includes five by where and driven in exit review I'll Healthcare equity by which Pharmaceutical, X, consolidated per by branded market in activity by weighted generic XX offset tax-free volumes, approximate an end shares outstanding investments These quarter be the XXX up growth year. to Adjusted results, in X% million. headwind and segment net third growth and driven $XXX share, fiscal X%, found which lowered in including successful the growth. shares at X% US with by earnings Wrapping $X.XX the can per initiatives, addition increased through $XX were partially decrease diluted million conversions. segment investment. Change diluted diluted to be approximately our share repurchase profit quarter of prior investment specialty a revenues year-over-year with in XX% offset average Third operating for by next, $XX.X expect We shares were million operating outstanding fiscal of partially slides support share And for of or now point billion, pretax million, XXXX, XXX higher of which to is our to million, XXXX McKesson's approximately accounted strategic
negatively light flu Our were colder also season. segment by results the impacted
December, outlook activity for vaccine timing to immaterial detail trended expectations. were our price distribution the Moderna's third distribution later in Given more line related our the my remarks. the provide COVID-XX of of related in earnings with third in to quarter. in quarter, I'll And approval COVID-XX the vaccine on FDA branded vaccines
in maintaining on manufacturer our mid-single digit price branded are based in range. assumption actions the we year price to fiscal be Additionally, taken XXXX January, full increases of percent
billion, Next, the Canadian The the effective Alliance, distribution the was our lower by International. as the fiscal Walgreens in On customer Pharmaceutical joint year. newly had XXXX. to due exit which of Revenues business, Boots $X.X of November decreased revenues FX-adjusted contribution at also wholesale Xst, beginning segment decrease of X% volumes largely to the XX%, of unprofitable an driven basis, venture an German with primarily were of year-over-year. business a the formed
to of to $XXX profit X% profit driven adjusted two X% European Excluding German compared was basis, operating basis. increased primarily Adjusted an the year-over-year FX-adjusted year-over-year the sell year. prior divestiture increased by in and on On to flat segment FX-adjusted wholesale impact operating an million. $XXX days the our increased business, additional business from million, revenue the X%
on to Solution. Now Medical-Surgical moving
mobility Our Medical-Surgical patient pleased the to of the We levels quarter tests levels. by segment pre-COVID demand COVID-XX also business, We're have trailing despite and continues experienced to uneven solid for unpredictable in often COVID-XX growth be impacted to related and the core demand delivered PPE. strong pandemic. throughout
segment, solutions, and pandemic. US the our and resilient as QX we're with been Pharmaceutical And of the such breadth providers capabilities, to brands patient private patients throughout customers home Primary supporting have Our driven delivery. the Care their lab and results Similar light were primarily the Revenues by billion continue businesses. the this season, of colder demand Extended our impacted XX%, Primary in quarter, expect tests in to the throughout up were fiscal the Care by also remainder COVID-XX $X.X and and for we year. flu Extended
PPE. to As elevated been of tests quarter market, volatile on, elevated is This these access has our to need demand the from items for patients. meet our third patient unpredictable supplies, Medical-Surgical on IQVIA. customers supply demand products some which at and including demands and and impacts quarter to experienced business hospitalizations recorded quarter second in third for focus to the to mobility charges a according In the quickly we cases we the results, million levels, highest procured providing and levels our customers Throughout our pandemic, these they always, related meeting due highly as in again and with products. built impacting uneven their the dynamics, reflected COVID-XX call, to and in XX% needs treat discussed demand PPE to Early supply inventory times their continue quarter, procedures, and levels of the reached our PPE XX% of elective related down the COVID-XX and to as were that we to charges. these our patients, $XX Due of pandemic.
quarter, the COVID-XX driven partially operating by and XX% for For distribution adjusted by on million, demand tests contribution ancillary PPE-related vaccines, inventory the to charges for $XXX products. and the increased offset kitting profit of from COVID-XX certain the supplies
XX% profit test, the the incremental in of impact adjusted up Excluding third is PPE COVID-XX in the the quarter. year-over-year operating segment and
programs. $XXX X%, organic were of increase Adjusted driven and Revenues growth to profit the increased driven Next, business. million, Prescription new Solutions. volumes support Technology in by brand higher of $XXX existing by operating XX% an million,
to the our recognize discussed investment are earlier. in expansion we benefits investments, the our Brian which our for starting invest such AMP, in of biopharma customers, to of continue as offerings technology these we While
on adjusted corporate X% partially Corporate, by was Ventures in as approximately offset to recorded expenses, $XXX million year-over-year, driven within interest increase income. an McKesson investments our the of on employee expenses lower decrease portfolio. as in million This quarter, a Moving by equity of well gains in McKesson $XX
value had several fair Ventures. This we to our companies quarter, portfolio adjustments within related of McKesson
on therefore, we million. call, opioid-related our XXXX, And quarter predict be mentioned portfolio in continue been impacts that in guidance. approximately be litigation $XX expenses will portfolio Ventures include fiscal million for and the $XXX we of anticipate opioid-related will difficult costs I reported when Venture finally, As our and second quarter not our occur may losses companies or our has on it's practice gains to to and
to quarter billion. generated first a free we can of now for $XXX $X.X we cash months balance - Turning found ended which fiscal the million. with flow the be And nine slide cash, of cash of the on year, XX,
from working day that timing, in impacted In the cash and the QX, the we a capital flow In again quarter. primarily dynamics quarter-to-quarter, of cash result have COVID 'XX, close flow quantities of of from our Our by week levels demand. of also including free levels marks metrics by saw inventory, been resulting impacted of PPE. tests can vary higher customer fiscal increased changing
government, internal the kitting to support and includes needs technology, Oncology we work our strategic of expenditures, made may experience analytics investments efforts of million our meet Biopharma COVID-XX volatility. As working with our and the we we to and to vaccine customers and services. support $XXX work capital US capital Year-to-date, initiatives and ramp-up data, evolving our additional of investments
of our share through nine shareholders the first months in $XXX $XXX returned cash the $XXX dividends. of million to payment of year, repurchases million and million For fiscal of the we
Let a pandemic for me declines businesses balance quarter, quarter, by and impact sharp continue through XXXX. our our the trajectory to second in The across COVID-XX our of of effects first now followed indicated the turn in virus signs stabilization. our of communities more the outlook positive different to The ways. fiscal
important However, our today. of as about third the talking been the led assumptions non-linear shape the we've guidance of case underpinned increased in to a softening Two the reiterating another and the recovery fiscal XXXX, hospitalizations good third of all and that those was counts trends have quarter quarter. throughout year, we're example
for expect anticipated we our initially that health we've product second, services. assume not fiscal continue kits to and will demand into elevated levels consumption line, would levels to these lead the of which we COVID-XX be volume our care the a there COVID-XX do categories. ultimate Through in home also take straight and PPE. pandemic and shelter of event. in be the we assume which volatility recovery customer we reiterate any seen that economic lockdown, patient do of the believe impacts will preclude will like XXXX. significant longer of will as Further, and third test persist would quarter, do mobility and that to a not at And new First, systemic wave insolvency not I'd than
COVID-XX guidance dynamic scope accordance vaccine account these into within expect do distribution, volumes CDC. in the schedule that provided COVID-XX we McKesson's given contract, approved earnings is Also, However, the moderate. of our to will now vaccine now there an distribution is takes the related McKesson with to by
year, distribution previous third our $XX.XX are COVID-XX tied to $XX estimated now earnings of includes for to we outlook vaccines, range performance of to from which the of and increasing earnings guidance adjusted result a $XX.XX the of and our narrowing to As $XX.XX. range solid quarter the our remainder
increase X% the our an between for to anticipate full the results consolidated operating grow revenues and to guidance up continue for we X% to which consolidated prior X%. expect from year, to is Change of adjusted prior fiscal profit now the X% from the We excluding X% between XXXX. of And will increase Healthcare year, X%
our moving COVID-XX net we operating adjusted and now continue benefit year. X% compared is $X. to in guidance final approximately segment, of as factors, role continued X% XX included prior Now of to centralized to We've volumes our diluted includes $X.XX a EPS headwind equates International extend mix product remind half segment leading X% $X.XX our CDC. to and of now in our making we to of fiscal and to I profit a incremental which XXXX. invest we operating second adjusted to investments year-over-year XXXX, of fiscal adjusted the for decline our X% the profit to expect by the In dependent are $X.XX as earnings you which XXXX This to position segment, per the distributor revenue growth commitment US related segments. approximately our Oncology, share vaccine. Pharmaceutical of in distribution the the to number X% in also on of to range growth. for fiscal to vaccine expect and to would a adjusted of where to revenue X% In to grow be directed expect X% X%
me to recovery a variable market. pattern and of the within remains turn pivotable path Medical-Surgical. supply Medical-Surgical Let shifting now The COVID-XX
levels referenced test of elevated COVID-XX quarter, demand and throughout I we kits see for earlier, third continued to As PPE. the
in anticipate moderate. will we We which shift see expect volumes, to
are these and segment, in remainder of sales for expect to levels the our year. We a factored into opportunity fiscal be demand the of our near-term guidance elevated
million. we we adjusted with $XXX kit expanded Technology range improved expanded we Due approximately supply between the our administration our FY XX% ancillary $X.XX of quarter the outlook, to will kitting revenue from supplies XXXX approximately to XX%. In profit now be expect our vaccine. scope, expect of sites storage the and During contracted to now of in And COVID-XX corporate of and the ancillary prior the operating vaccine increase a related segment, the now directed in now Pfizer on $X.XX ancillary HHS as in contract this profit expect million in grow X% 'XX expect a operating expected of contribution to to range revenue $XXX grow to with expect we behalf. COVID-XX third also we adjusted expect result performance and to Solutions we distribute and benefit supplies, quarter, the flat kitting ancillary and now XX% including to Prescription increase fiscal for the to and to to their kits distribution our X% XX%. of to assembly expenses for year. finally, the of distribution segment And Therefore, Medical-Surgical and
with me our outlook deployment. up Let capital wrap
to continue billion of to billion. We $X.X approximately cash flow free $X.X expect
for a of committed cash dividend the Oncology As majority capital cash through to execute a capital in shareholders return to business Services, generated allocation have This investing our our and of in our the positioning repurchases. we remaining long-term approach, year. flexibility to financial balanced our strong fourth historically strategies share our of Biopharma fiscal and provides growth, flow generation the quarter while reminder,
strengthened Our priority portion financial evidenced our bond balance credit third of $XXX actions, our to a and delever, position. attractive with proud despite of with rates. we QX, our sheet in of financial across and the I'm in fiscal drive million were pleased $X quarter at execution the our for stated In as fiscal our feel which in remains These and a continued of outlook the rating year. a Investing focus business, the debt, confident remainder to and and we're our we closing, results updated intent underpins investment backdrop. priority, line in our strategies further and investment-grade retire flexibility. In of flow macroeconomic billion market by approximately in our challenging further we've differentiation positions utilized issued a the outlined free we in our as a Services, Ontada. Oncology our remains we cash Biopharma modestly
pandemic call As COVID-XX need into US forward working to And me to supplies the that, you turn get a over Q&A. in government vaccines that let continuing effort, proud for Holly, of and back vaccine our the and partner to look the them. we the communities the role response, ancillary with
